港股異動丨獲券商看好 騰盛博藥(2137.HK)續升超5% 2日漲幅達40%
格隆匯11月16日丨昨日大漲35.2%的騰盛博藥(2137.HK)繼續拉昇超5%,報31.2港元,總市值223億港元。公司新冠病毒聯合療法日前提交FDA緊急使用授權。中金認為,初步證明研發和臨牀開發能力,有望在短期內貢獻收入。報吿認為,騰盛博藥的佈局有望實現差異化競爭。此外,認為公司將通過新冠中和抗體,完成一家生科公司從臨牀階段到商業化的轉變,證明了公司在中美兩地研發,註冊和商業化的實力。首予公司跑贏行業評級。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.